Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Naturhouse HealthXMAD:NTH +1.98%75 EV-to-EBITDA is 9.56 as of Jul. 26, 2026, which is 75% above its 10-year median of 5.45. GuruFocus rates XMAD:NTH with a GF Score™ of 75/100 and a GF Value™ of €1.62 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 1,643 Consumer Packaged Goods companies, Naturhouse Health ranks worse than 53.5% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Naturhouse Health's enterprise value is €142.64 Mil.
Naturhouse Health's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was €14.92 Mil. Therefore, Naturhouse Health's EV-to-EBITDA for today is 9.56.
The historical rank and industry rank for Naturhouse Health's EV-to-EBITDA or its related term are showing as below:
XMAD:NTH'
s EV-to-EBITDA Range Over the Past 10 Years
Min: 2.83 Med: 5.45 Max: 9.8
Current: 9.56
During the past 13 years, the highest EV-to-EBITDA of Naturhouse Health was 9.80. The lowest was 2.83. And the median was 5.45.
XMAD:NTH's EV-to-EBITDA is ranked worse than 53.5% of 1643
companies
in the Consumer Packaged Goods industry
Industry Median: 9.04
vs XMAD:NTH: 9.56
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio (TTM).
Naturhouse Health (XMAD:NTH) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Naturhouse Health's PE Ratio (TTM) for today is calculated as:
Naturhouse Health's share price for today is €2.58.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Naturhouse Health's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was €0.170.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Naturhouse Health's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XMAD:NTH vs KHC, GIS, HRL: EV-to-EBITDA Comparison
For the Packaged Foods subindustry, Naturhouse Health's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Naturhouse Health EV-to-EBITDA vs Consumer Packaged Goods Industry
For the Consumer Packaged Goods industry and Consumer Defensive sector, Naturhouse Health's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Naturhouse Health's EV-to-EBITDA falls into.
Naturhouse Health's current Enterprise Value is €142.64 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Naturhouse Health's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was €14.92 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Naturhouse Health (XMAD:NTH) has a EV-to-EBITDA of 9.56 as of Jul. 26, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Naturhouse Health. This is 75% above median its historical median of 5.45. Over the past decade, Naturhouse Health's EV-to-EBITDA has ranged from 2.83 to 9.80. According to the industry distribution chart, Naturhouse Health ranks #879 out of 1643 companies in the Consumer Packaged Goods industry, placing it in the top 53.5%.
Is Naturhouse Health's EV-to-EBITDA too high?
Naturhouse Health's current EV-to-EBITDA of 9.56 is 75% above median its 10-year median of 5.45. Over the past 10 years, this metric has ranged from a low of 2.83 to a high of 9.80. The Consumer Packaged Goods industry median EV-to-EBITDA is 9.04. Naturhouse Health's value of 9.56 is 5.8% above this industry median. Based on the distribution chart, Naturhouse Health ranks #879 out of 1643 companies in the Consumer Packaged Goods industry, which is below the industry midpoint. Overall, Naturhouse Health has a GF Score™ of 75/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Naturhouse Health's EV-to-EBITDA compare to KHC and GIS?
According to the Consumer Packaged Goods industry distribution chart, Naturhouse Health ranks #879 out of 1643 companies for EV-to-EBITDA. This places Naturhouse Health in the lower half of its industry. The industry median EV-to-EBITDA is 9.04. Naturhouse Health's value of 9.56 is 5.8% above this benchmark. Historically, Naturhouse Health's own EV-to-EBITDA has ranged from 2.83 to 9.80 over the past decade. While the company's 10-year median is 5.45 vs. the industry median of 9.04, Naturhouse Health has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Consumer Packaged Goods company?
The median EV-to-EBITDA among Consumer Packaged Goods companies is 9.04, based on 1,643 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Naturhouse Health's current EV-to-EBITDA of 9.56 is 5.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Naturhouse Health. For the Consumer Packaged Goods industry, the median EV-to-EBITDA is 9.04 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Naturhouse Health's current EV-to-EBITDA is 9.56, which is 75% above median its own 10-year median of 5.45. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Naturhouse Health stock overvalued right now?
Based on GuruFocus' analysis, Naturhouse Health (XMAD:NTH) is currently considered Significantly Overvalued. The stock's GF Value™ is €1.62, compared to a current price of €2.58 — trading 59.3% above its estimated fair value. The current EV-to-EBITDA is 9.56, which is 75% above median its 10-year median of 5.45 and 5.8% above the Consumer Packaged Goods industry median of 9.04. Naturhouse Health's overall GF Score™ is 75/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Naturhouse Health (XMAD:NTH), the current EV-to-EBITDA is 9.56 as of Jul. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Naturhouse Health (XMAD:NTH) Overvalued in 2026?
Based on GuruFocus' analysis, Naturhouse Health stock appears to be overvalued.
The current stock price of €2.58 is trading 59.3% above its estimated GF Value™ of €1.62.
GuruFocus considers Naturhouse Health to be Significantly Overvalued.
Key valuation signals for XMAD:NTH:
EV-to-EBITDA: 9.56 (75% above median its 10-year median of 5.45)
GF Value™: €1.62 vs. price of €2.58 (59.3% above fair value)
Industry Position: 5.8% above the Consumer Packaged Goods median (#879 of 1643)
No single metric tells the full story. See the XMAD:NTH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Naturhouse Health SA provides nutrition & weight management products. The activity of the company is the export, wholesale, and retail sales of all kinds of products related to dietetics, herbal remedies, and natural cosmetics, as well as the preparation, promotion, creation, edition, dissemination, sale, and distribution of all kinds of magazines, books, and brochures and the marketing of dietary products, herbal remedies, and natural cosmetics. This activity is mainly carried out through franchisees and its stores. The geographical segments of the company are Spain, France, Italy, Poland, and Other countries.
75GF Score
Get the complete analysis for XMAD:NTH
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XMAD:NTH has been successfully added to your 
